Happy Holidays!
As we reflect on 2024, we’d like to share some of our achievements with you and express our gratitude to our patients and donors. These successes would not have been possible without your help.
At MiraKind, our mission is to educate people about our unique class of genetic biomarkers, advance research on these markers to identify new ways to prevent and treat diseases, and enable access to their meaningful applications. This mission serves as the foundation for all our achievements.
Together, we are making this happen! Please see the ways we worked towards this mission for each category below:
This year we released six patient stories that detailed the challenges they were facing, the sense of empowerment they gained after receiving results from their KRAS-variant or PROSTOXTM tests, and how the tests helped them make well-informed treatment decisions.
Knowledge is power! We published five blogs that aimed to provide patients with up-to-date scientific information on prostate cancer, breast cancer, and Alzheimer’s. Our goal is to help patients make informed personal decisions about their treatments.
Hormone Replacement Therapy (HRT) Study
With the participation of 1,500 women, we were able to use our unique genetics to better understand how HRT affects women’s breast cancer risk.
PROSTOXTM ultra Testing Access
- Gave prostate cancer patients access to testing that predicts if they are high-risk of toxicity from stereotactic body radiotherapy (SBRT).
- Gave prostate cancer patients access to testing that predicts if they are high-risk of toxicity from another radiation method, conventionally fractionated radiation therapy (CFRT).
To support our mission, we ran our second ASICS Falmouth Road Race for MiraKind! Thanks to our donors, we raised nearly $23,000! Want to help us achieve our goals? It’s not too late to make a 2024 donation!
That brings 2024 to a close, but keep an eye out for 2025—it promises to be an exciting year! We are in the beginning phases of researching genetic markers for colorectal cancer, sarcomas, breast cancer, and head and neck cancer, and plan to make progress on our HRT and breast cancer risk study. Our focus is to continue developing new tests to make it easier to identify the best course of treatment for patients, potentially leading to a cure and/or minimizing the risks of toxicity.
